Health
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the market...
2024-04-08 22:00
1437
Medit Unveils i900: The Next Evolution of Intraoral Scanners
Secure a front-row seat for the debut of Medit i900 and discover the latest
cutting-edge dental technology
SEOUL, South Korea and LONG BEACH, Calif., April 8, 2024 /PRNewswire/ --
Medit (www.medit.com
2024-04-08 21:00
1405
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
- Employing Lunit INSIGHT MMG, a Turkish study showcases 70% efficiency improvements, advancements in early cancer detection, and interval cancer detection in mammography SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cance...
2024-04-08 21:00
1836
SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego
Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds in Retrospective and Prospective Settings Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict the Tissue of Origin of Ca...
2024-04-08 20:00
1244
D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline
SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm. D3 Bio'...
2024-04-08 15:00
1375
Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024
SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research...
2024-04-08 08:30
1237
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, April 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it releases the latest results from three pre...
2024-04-08 07:58
1477
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for patients with locally advanced or metastatic non-small cell lung can...
2024-04-07 19:09
1963
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at th...
2024-04-05 19:00
1902
IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis
SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 4, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, is pleased to announce that the Inve...
2024-04-05 08:00
1827
Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting
BEIJING, April 4, 2024 /PRNewswire/ -- Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microen...
2024-04-04 22:00
1703
Datasea Enters into a Sales Agreement for its Acoustic Products Bringing its Evolutionary Technology to Market in a Strategic Milestone to Develop Rapid Online Sales
BEIJING, April 4, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and C...
2024-04-04 22:00
2022
China Medical University Hospital (CMUH) Explores ' BrainHealth ' to Scrutinize Dementia within a Minute
TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- In clinical practice, neurologists scrutinize dementia patients with using numerous tools, including medical history, blood tests, cognitive testing, mental assessment, medical imaging and electro-physiological signal testing. Patients usually spend...
2024-04-04 20:30
2853
China Medical University Hospital (CMUH) Ranked Global No.1 Smart Hospital in HIMSS Digital Health Indicator 2023
CMUH has been awarded DHI top hospitals twice in a row TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) has achieved a global top score, 370/400, for the Healthcare Information and Management Systems Society (HIMSS) Digital Health Indicator（DHI）in 2023. T...
2024-04-04 20:30
2514
SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024
TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based inTaiwan, is proud to announce its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will ...
2024-04-04 01:00
1520
China Medical University Hospital (CMUH) Inventing "Intelligent Urine Sediment Morphology Analysis, IUSMA" to Find Chronic Glomerulonephritis in Just 10 Minutes
TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- The urine sediment examination is primarily used to detect and assess kidney and urinary system health. In the conventional practice, a urine sediment test covers six items: red blood cells, white blood cells, squamous cells, urinary casts, crystals...
2024-04-03 20:30
1498
CMUH (Taiwan) Launches "Intelligent Sepsis Early Prediction System (ISEPS)," Detecting Sepsis in One Minute Only
It is the world's first AI-Powered sepsis alert system to save more lives TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- In conventional practice, a blood culture report wouldn't be available until 18 to 72 hours later, rendering it non-feasible to facilitate rapid response. Led by Superintend...
2024-04-03 20:30
1639
China Medical University Hospital (CMUH) Launches "Intelligent Microbiome Evaluation- iME" to Detect Intestinal Bad Bacteria and Empowers Personalized Gut Health
Patients with diarrhea and cramps have benefited greatly from iME TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- Gastrointestinal (GI) examinations can be invasive or non-invasive. Stool tests (non-invasive) can be associated with limitations such as the amount of pathogens present being too ...
2024-04-03 20:30
1586
Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC
JIANGSU, China, April 3, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone today with the first patient dosed in its First-in-human phase I clinical trial for RAG-01 conducted in collaboration with GenesisCare,Australia'...
2024-04-03 20:00
1364
Ascletis Announces Strategic Decisions on FXR agonist ASC42
HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (...
2024-04-03 17:10
1929
Week's Top Stories
Most Reposted
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
[Picked up by 313 media titles]
2024-11-12 09:00
DKSH Healthcare and Euris Unveil CRM & MCE Platform "ConnectPlus" to Revolutionize APAC Healthcare Distribution
[Picked up by 293 media titles]
2024-11-13 09:00
Sobot Introduces its All-in-One Solution at GITEX Global 2024
[Picked up by 291 media titles]
2024-11-12 11:00
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
[Picked up by 289 media titles]
2024-11-11 21:00
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
[Picked up by 279 media titles]
2024-11-08 20:11
Most Read
Ubiqconn Technology to Showcase Latest Marine Solutions at the 2024 International WorkBoat Show in New Orleans
2024-11-11 21:00
5634
DND International Eye Hospital: Pioneering SMILE Pro Surgery & Leading the Trend of Refractive Surgery Tourism in Vietnam
2024-11-08 20:11
5568
HOIANA RESORT & GOLF LAUNCHES PREMIUM HOIANA PICKLEBALL COURT
2024-11-08 00:18
5520
Going Global: DCITS Embarks on International Expansion at Singapore Fintech Festival
2024-11-12 09:00
5403